SCHEMBL5657693

SCHEMBL5657693

CC(C)C(=O)Nc1cccc(C2CCN(CCCOc3ccc(F)cc3)CC2)c1

nearest known ligand 0.71

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 8/20 0.62
ADRA1A P35348 2/20 0.62
MCHR1 Q99705 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5661568 0.92 DRD2 (0.61) DRD2ADRA1A
SCHEMBL5661275 0.91 DRD2 (0.61) DRD2ADRA1A
SCHEMBL5662177 0.91 DRD2 (0.74) DRD2ADRA1AMCHR1
SCHEMBL6082295 0.89 DRD2 (0.71) DRD2ADRA1A
SCHEMBL14619661 0.89 DRD2 (0.57) DRD2ADRA1AMCHR1
SCHEMBL5660955 0.88 DRD2 (0.60) DRD2ADRA1AMCHR1
SCHEMBL5660701 0.88 DRD2 (0.61) DRD2ADRA1A
SCHEMBL5661088 0.87 DRD2 (0.62) DRD2ADRA1AMCHR1
SCHEMBL5659244 0.87 DRD2 (0.62) DRD2ADRA1AMCHR1
SCHEMBL5659500 0.87 DRD2 (0.69) DRD2ADRA1AMCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070043080-A1 Substituted anilinic piperidines as MCH selective antagonists MARZABADI MOHAMMAD R 2007-02-22 US disclosed
US-20070043080-A1 Substituted anilinic piperidines as MCH selective antagonists MARZABADI MOHAMMAD R 2007-02-22 US disclosed
US-7067534-B1 Substituted anilinic piperidines as MCH selective antagonists H. LUNDBECK A/S (DK) 2006-06-27 US disclosed
US-6727264-B1 MELANIN CONCENTRATING HORMONE-1 RECEPTOR ANTAGONISTS; SLEEP, EATING, SEXUAL DISORDERS SYNAPTIC PHARMACEUTICAL CORPORATION 2004-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043080-A1 Substituted anilinic piperidines as MCH selective antagonists MCHR1, MCHR2, MC1R DRD2 119/4885ADRA1A 46/4885MCHR1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.